CY1121529T1 - Σηματοδοτηση slit-robo για διαγνωση και θεραπεια νεφρικης νοσου - Google Patents
Σηματοδοτηση slit-robo για διαγνωση και θεραπεια νεφρικης νοσουInfo
- Publication number
- CY1121529T1 CY1121529T1 CY20191100151T CY191100151T CY1121529T1 CY 1121529 T1 CY1121529 T1 CY 1121529T1 CY 20191100151 T CY20191100151 T CY 20191100151T CY 191100151 T CY191100151 T CY 191100151T CY 1121529 T1 CY1121529 T1 CY 1121529T1
- Authority
- CY
- Cyprus
- Prior art keywords
- kidney disease
- slit
- treatment
- diagnosis
- robo signaling
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
Στο παρόν παρέχονται μέθοδοι για την θεραπεία χρόνιας νεφρικής νόσου και πρωτεϊνουρίας και για την διάγνωση χρόνιας νεφρικής νόσου και παρακολούθησης των αποτελεσμάτων της θεραπείας στην εξέλιξη της χρόνιας νεφρικής νόσου και πρωτεϊνουρίας βάσει των μη αναμενόμενων ρόλων του μονοπατιού σηματοδότησης SLIT-ROBO στην ρύθμιση του κυτταροσκελετού F-ακτίνης των ποδοκυττάρων και της διαδικασίας δομής ποδοειδών προεκβολών στον νεφρό.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261583379P | 2012-01-05 | 2012-01-05 | |
PCT/US2013/020280 WO2013103811A2 (en) | 2012-01-05 | 2013-01-04 | Slit-robo signaling for diagnosis and treatment of kidney disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121529T1 true CY1121529T1 (el) | 2020-05-29 |
Family
ID=48745540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100151T CY1121529T1 (el) | 2012-01-05 | 2019-02-04 | Σηματοδοτηση slit-robo για διαγνωση και θεραπεια νεφρικης νοσου |
Country Status (29)
Country | Link |
---|---|
US (2) | US9572879B2 (el) |
EP (1) | EP2800578B1 (el) |
JP (2) | JP6153946B2 (el) |
KR (1) | KR102103323B1 (el) |
CN (2) | CN104271197A (el) |
AU (2) | AU2013207484B2 (el) |
BR (1) | BR112014016493A2 (el) |
CA (1) | CA2860558C (el) |
CO (1) | CO7020918A2 (el) |
CY (1) | CY1121529T1 (el) |
DK (1) | DK2800578T3 (el) |
ES (1) | ES2714700T3 (el) |
HK (1) | HK1202085A1 (el) |
HR (1) | HRP20190116T1 (el) |
HU (1) | HUE041779T2 (el) |
IL (1) | IL233462B (el) |
LT (1) | LT2800578T (el) |
MX (1) | MX351313B (el) |
MY (1) | MY170143A (el) |
PE (1) | PE20141473A1 (el) |
PH (2) | PH12018502577A1 (el) |
PL (1) | PL2800578T3 (el) |
PT (1) | PT2800578T (el) |
RS (1) | RS58517B1 (el) |
RU (1) | RU2674153C2 (el) |
SG (2) | SG11201403746SA (el) |
SI (1) | SI2800578T1 (el) |
TR (1) | TR201821294T4 (el) |
WO (1) | WO2013103811A2 (el) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014194402A1 (en) * | 2013-06-04 | 2014-12-11 | The Hospital For Sick Children | Methods and uses of slit for treating fibrosis |
WO2016022437A1 (en) * | 2014-08-08 | 2016-02-11 | Icahn School Of Medicine At Mount Sinai | Electronic phenotyping technique for diagnosing chronic kidney disease |
KR102011957B1 (ko) | 2016-06-08 | 2019-08-19 | 재단법인 아산사회복지재단 | Slit-robo 시스템을 이용한 근감소증 예방 또는 치료용 조성물 |
WO2017213435A1 (ko) * | 2016-06-08 | 2017-12-14 | 재단법인 아산사회복지재단 | Slit-robo 시스템을 이용한 근감소증 예방 또는 치료용 조성물 |
WO2018070346A1 (ja) | 2016-10-11 | 2018-04-19 | 国立大学法人徳島大学 | 腎臓様組織の製造方法 |
EP3602045A1 (en) * | 2017-03-25 | 2020-02-05 | Charité - Universitätsmedizin Berlin | Urine flow cytometry as biomarker of renal diseases |
CN108929383B (zh) * | 2017-05-26 | 2021-10-15 | 阿思科力(苏州)生物科技有限公司 | 重组Slit2D2(C386S)-HSA融合蛋白及其在预防和/或治疗肺部炎症中的应用 |
AU2018278809B2 (en) * | 2017-06-02 | 2022-03-31 | Boston Medical Center Corporation | Recombinant ROBO2 proteins, compositions, methods and uses thereof |
CA3061986A1 (en) | 2017-06-09 | 2018-12-13 | Pfizer Inc. | Anti-robo2 antibodies, compositions, methods and uses thereof |
WO2019038772A1 (en) | 2017-08-24 | 2019-02-28 | Bar-Ilan University | ROUNDABOUT FAMILY RECEPTOR INHIBITORS (ROBO) AND CORRESPONDING USES THEREOF |
CN108753818B (zh) * | 2018-04-24 | 2022-01-28 | 深圳市第二人民医院 | RNA信号连接器、靶mRNA翻译调控方法、逻辑门及应用 |
JP2021527232A (ja) * | 2018-06-15 | 2021-10-11 | マイクロビーエー アイピー ピーティーワイ リミテッドMicroba Ip Pty Limited | 試料調製及びマイクロバイオーム特徴づけのための方法 |
BR112021021092A2 (pt) * | 2019-04-23 | 2023-02-28 | Univ California | Composições e métodos úteis na promoção de produção de leite |
EP3998090A4 (en) | 2020-05-29 | 2023-08-02 | Rokit Healthcare Inc. | KIDNEY TREATMENT COMPOSITION USING OMENTUM, MEDICAL TREATMENT KIT THEREOF AND KIDNEY TREATMENT FILM WITH CURED PRODUCT THEREOF |
CN115068480B (zh) * | 2022-08-09 | 2023-10-20 | 郑州大学第一附属医院 | 细胞分裂周期蛋白42小分子抑制剂在制备治疗慢性肾脏病药物中的应用 |
WO2024061158A1 (en) * | 2022-09-20 | 2024-03-28 | Everest Medicines (China) Co., Ltd. | Slit2 related compositions and methods |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
GB2236186B (en) | 1989-08-22 | 1994-01-05 | Finnigan Mat Gmbh | Process and device for laser desorption of analyte molecular ions, especially of biomolecules |
US5045694A (en) | 1989-09-27 | 1991-09-03 | The Rockefeller University | Instrument and method for the laser desorption of ions in mass spectrometry |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
NZ267842A (en) | 1993-05-28 | 1997-09-22 | Baylor College Medicine | Apparatus for measuring molecular mass (by mass spectrometry) in which the sample is ionised on the sample holder and desorbed therefrom by laser pulses |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
AU729496B2 (en) | 1997-10-20 | 2001-02-01 | Regents Of The University Of California, The | Robo: a novel family of polypeptides and nucleic acids |
US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
US20030077616A1 (en) | 2001-04-19 | 2003-04-24 | Ciphergen Biosystems, Inc. | Biomolecule characterization using mass spectrometry and affinity tags |
EP1425695A2 (en) | 2001-08-13 | 2004-06-09 | Beyong Genomics, Inc. | Method and system for profiling biological systems |
ES2431040T3 (es) * | 2002-03-08 | 2013-11-22 | Shanghai Institutes For Biological Sciences, Cas | Detección y modulación de la angiogénesis mediada por Slit y Roundabout (Robo), y sus usos |
US20030199001A1 (en) | 2002-04-23 | 2003-10-23 | Pitt Aldo M. | Sample preparation of biological fluids for proteomic applications |
WO2007022248A2 (en) | 2005-08-16 | 2007-02-22 | Sloan Kettering Institute For Cancer Research | Methods of detection of cancer using peptide profiles |
FR2958936A1 (fr) | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
EP2655408B1 (en) | 2010-12-23 | 2016-07-06 | Sanofi | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma |
-
2013
- 2013-01-04 DK DK13733786.1T patent/DK2800578T3/en active
- 2013-01-04 PT PT13733786T patent/PT2800578T/pt unknown
- 2013-01-04 KR KR1020147021856A patent/KR102103323B1/ko active IP Right Grant
- 2013-01-04 PH PH12018502577A patent/PH12018502577A1/en unknown
- 2013-01-04 MY MYPI2014701826A patent/MY170143A/en unknown
- 2013-01-04 PE PE2014001066A patent/PE20141473A1/es not_active Application Discontinuation
- 2013-01-04 RU RU2014132108A patent/RU2674153C2/ru active
- 2013-01-04 CN CN201380012919.6A patent/CN104271197A/zh active Pending
- 2013-01-04 MX MX2014008088A patent/MX351313B/es active IP Right Grant
- 2013-01-04 HU HUE13733786A patent/HUE041779T2/hu unknown
- 2013-01-04 CA CA2860558A patent/CA2860558C/en active Active
- 2013-01-04 RS RS20190250A patent/RS58517B1/sr unknown
- 2013-01-04 SG SG11201403746SA patent/SG11201403746SA/en unknown
- 2013-01-04 AU AU2013207484A patent/AU2013207484B2/en active Active
- 2013-01-04 LT LTEP13733786.1T patent/LT2800578T/lt unknown
- 2013-01-04 PL PL13733786T patent/PL2800578T3/pl unknown
- 2013-01-04 BR BR112014016493-2A patent/BR112014016493A2/pt not_active Application Discontinuation
- 2013-01-04 WO PCT/US2013/020280 patent/WO2013103811A2/en active Application Filing
- 2013-01-04 US US14/369,094 patent/US9572879B2/en active Active
- 2013-01-04 TR TR2018/21294T patent/TR201821294T4/tr unknown
- 2013-01-04 ES ES13733786T patent/ES2714700T3/es active Active
- 2013-01-04 SI SI201331331T patent/SI2800578T1/sl unknown
- 2013-01-04 SG SG10201605361RA patent/SG10201605361RA/en unknown
- 2013-01-04 EP EP13733786.1A patent/EP2800578B1/en active Active
- 2013-01-04 CN CN201610836378.4A patent/CN106390118B/zh active Active
- 2013-01-04 JP JP2014551337A patent/JP6153946B2/ja active Active
-
2014
- 2014-06-30 IL IL233462A patent/IL233462B/en active IP Right Grant
- 2014-07-03 PH PH12014501538A patent/PH12014501538B1/en unknown
- 2014-07-30 CO CO14165787A patent/CO7020918A2/es unknown
-
2015
- 2015-03-10 HK HK15102468.2A patent/HK1202085A1/xx unknown
-
2017
- 2017-01-06 US US15/399,848 patent/US10358677B2/en active Active
- 2017-05-31 JP JP2017107263A patent/JP2017193559A/ja active Pending
-
2018
- 2018-01-05 AU AU2018200105A patent/AU2018200105A1/en not_active Abandoned
-
2019
- 2019-01-18 HR HRP20190116TT patent/HRP20190116T1/hr unknown
- 2019-02-04 CY CY20191100151T patent/CY1121529T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121529T1 (el) | Σηματοδοτηση slit-robo για διαγνωση και θεραπεια νεφρικης νοσου | |
CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
CY1120246T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
UY34218A (es) | MÉTODO DE DETECCIÓN DEL EVENTO DE SOJA pDAB9582.814.19.1 | |
MX2016013635A (es) | Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes. | |
DK3311827T3 (da) | Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser | |
BR112012030592A2 (pt) | uso de composição nutricional enteral líquida, composição nutricional enteral líquida, método de prevenção ou tratamento de má nutrição ou baixa nutrição ou de reduzir o risco de ocorrência de má nutrição ou baixa nutrição em pacientes que sofrem de disfagia e método de prevenção ou tratamento de disfagia em mamíferos em risco de disfagia | |
PH12014501844B1 (en) | Peptidomimetic macrocycles | |
EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
WO2013033627A3 (en) | Diagnosis and treatment of arthritis using epigenetics | |
EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
MA34058B1 (fr) | Formes de rifaximine, et leurs utilisations | |
WO2014138429A3 (en) | Peptidomimetic macrocycles and use thereof in regulating hif1alpha | |
BR112015023207A2 (pt) | uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase | |
CL2016001076A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. | |
BR112015017241A2 (pt) | doadores de nitroxil com índice terapêutico melhorado | |
WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
CY1118968T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
EA201591543A1 (ru) | Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki | |
CY1120877T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης | |
EA201491894A1 (ru) | Способы лечения непереносимости лактозы | |
DK2988760T3 (da) | C. novyi til behandlingen af faste tumorer i mennesker | |
MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
RS54437B1 (en) | PROCEDURE FOR PREVENTION AND TREATMENT OF SEPS | |
BR112014002566A2 (pt) | método para tratar resíduo, e, dispositivo para o tratamento mecânico ou mecânico-biológico de resíduo. |